Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Rasna Therapeutics Inc. | ex321_5.htm |
| EX-31.2 - EXHIBIT 31.2 - Rasna Therapeutics Inc. | ex312_4.htm |
| EX-31.1 - EXHIBIT 31.1 - Rasna Therapeutics Inc. | ex311_3.htm |
| EX-24 - EXHIBIT 24 - Rasna Therapeutics Inc. | ex24_2.htm |
| EX-21 - EXHIBIT 21 - Rasna Therapeutics Inc. | ex21_1.htm |
| 10-K - 10-K - Rasna Therapeutics Inc. | rasp-20180930.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Interim Report of Rasna Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tiziano Lazzaretti, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Dated: December 21, 2018
|
/s/ Tiziano Lazzaretti
|
|
|
Name: Tiziano Lazzaretti
Title: Chief Financial Officer
|
|